Company
Fore Biotherapeutics
Leading the future of targeted therapies for the hardest to treat cancers
Also known as Fore Biotherapeutics, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Fore Biotherapeutics, Inc.
- fore.bio (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We are next-generation targeted oncology treatments aimed at patients with unaddressed mutations across well-established oncology targets.
Funding snapshot
- Total raised
- $67.4MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series D+, $67.4M2026-07-07
Funding rounds
- Series D+
- $67.4M2026-07-07, Company stated
Products
- Other
- Plixorafenib
- Web
- Plixorafenib
Loading relationship preview